Yoshimasa Aso

5.9k citations

160 papers · 4.3k indexed · 1 hit paper · h-index 35

Endocrinology, Diabetes and Metabolism top 0.5%
Epidemiology top 2%
Molecular Biology top 10%
Cardiology and Cardiovascular Medicine top 2%
Surgery top 5%

Co-authors: Toshihiko Inukai Kohzo Takebayashi Sadao Wakabayashi Teruo Jojima Kunihiro Suzuki Toshie Iijima Mariko Suetsugu K. Tayama
Topics: Diabetes Treatment and Management (30 papers)Adipokines, Inflammation, and Metabolic Diseases (22 papers)Diabetes Management and Research (17 papers)
Cited by: Endocrinology, Diabetes and Metabolism Epidemiology Clinical Biochemistry
Journals: SHILAP Revista de lepidopterologíaThe Journal of Clinical Endocrinology & Metabolism Diabetes Care
Partner nations: Japan United States Austria

In The Last Decade

Yoshimasa Aso

155 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

2018 286 citations Masanori Shimizu, Kunihiro Suzuki et al. profile →

Peers

Countries citing papers authored by Yoshimasa Aso

Since Specialization

Citations

This map shows the geographic impact of Yoshimasa Aso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshimasa Aso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshimasa Aso more than expected).

Fields of papers citing papers by Yoshimasa Aso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshimasa Aso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshimasa Aso. The network helps show where Yoshimasa Aso may publish in the future.

Co-authorship network of co-authors of Yoshimasa Aso

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshimasa Aso. A scholar is included among the top collaborators of Yoshimasa Aso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshimasa Aso. Yoshimasa Aso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Demonstration of autonomous fixed‐wing drone delivery of prescribed medications in remote islands in Japan 2025 ·Journal of General and Family Medicine ·(unknown),(unknown),Fumiaki Nonaka,Yoshimasa Aso,(unknown),Takahiro Maeda	0
2	High serum levels of CCL11/Eotaxin-1 are associated with diabetic sensorimotor polyneuropathy and peripheral nerve function but not with cardiac autonomic neuropathy in people with type 2 diabetes 2024 ·Postgraduate Medicine ·Yoshimasa Aso,Toshie Iijima,Teruo Jojima,Masahiro Saito,(unknown),(unknown),Shintaro Sakurai,Takuya Tomaru,Isao Usui	3
3	Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor 2023 ·Journal of Diabetes and its Complications ·(unknown),Teruo Jojima,Masaaki Hashiguchi,(unknown),(unknown),Shintaro Sakurai,Toshie Iijima,Takahiko Kogai,Takuya Tomaru,Isao Usui,Yoshimasa Aso	9
4	Increased Number of Mucosal-Associated Invariant T Cells Is Associated with the Inhibition of Nonalcoholic Fatty Liver Disease in High Fat Diet–Fed Mice 2022 ·International Journal of Molecular Sciences ·(unknown),Isao Usui,Teruo Jojima,Shiho Fujisaka,(unknown),(unknown),(unknown),Shintaro Sakurai,Toshie Iijima,Takuya Tomaru,Kazuyuki Tobe,Yoshimasa Aso	2
5	Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors 2022 ·Journal of Clinical Medicine ·Ikuko Shibasaki,Toshiaki Nakajima,Taira Fukuda,Takaaki Hasegawa,(unknown),(unknown),(unknown),(unknown),Takashi Kato,(unknown),Yasuyuki Kano,(unknown),(unknown),Shigeru Toyoda,Yoshimasa Aso,Hirotsugu Fukuda	4
6	Acute effect of add‐on therapy with tofogliflozin, a sodium glucose co‐transporter 2 inhibitor, on 24‐hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase‐4 inhibitors 2021 ·International Journal of Clinical Practice ·Toshie Iijima,(unknown),(unknown),(unknown),Shintaro Sakurai,Takuya Tomaru,Teruo Jojima,Isao Usui,Yoshimasa Aso	2
7	A case of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome with a novel frameshift variant in GATA3, p.W10Cfs40, lacks kidney malformation 2020 ·SHILAP Revista de lepidopterología ·(unknown),Teruo Jojima,Takahiko Kogai,Toshie Iijima,(unknown),(unknown),(unknown),Kanako Kato,(unknown),Kazumi Akimoto,(unknown),Akira Hishinuma,Takuya Tomaru,Noriko Makita,Isao Usui,Yoshimasa Aso	3
8	CD‐1^db/db mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis 2020 ·Journal of Diabetes Investigation ·(unknown),Keizo Kanasaki,Kyoko Nitta,Yuka Nakamura,Yasuhito Ishigaki,Yuta Takagaki,Munehiro Kitada,Shaolan Li,Haijie Liu,Jinpeng Li,Isao Usui,Yoshimasa Aso,Daisuke Koya	8
9	Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication 2020 ·SHILAP Revista de lepidopterología ·(unknown),Toshie Iijima,Shintaro Sakurai,Teruo Jojima,(unknown),Shujiro Hayashi,Isao Usui,Ken Igawa,Yoshimasa Aso	3
10	Evaluation of a Premixed Insulin Analog Suspension in Japanese People with Type 2 Diabetes and the Clinical Importance of Improved Injection Techniques: A Cross-Sectional Pilot Study 2017 ·Diabetes Therapy ·Kunihiro Suzuki,Chie Aoki,Kanako Kato,Masanori Shimizu,Shintaro Sakurai,Kazunori Yanagi,Hisamoto Kuroda,Yoshimasa Aso	1
11	Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice 2017 ·Atherosclerosis ·Teruo Jojima,Kohsuke Uchida,Kazumi Akimoto,(unknown),Kazunori Yanagi,Toshie Iijima,Kunihiro Suzuki,Kikuo Kasai,Yoshimasa Aso	91
12	Greater Efficacy and Improved Endothelial Dysfunction in Untreated Type 2 Diabetes with Liraglutide versus Sitagliptin 2014 ·Kunihiro Suzuki,Seiichi Tanaka,Chie Aoki,Kanako Kato,Teruo Jojima,Yoshimasa Aso	8
13	Add-On Treatment with Teneligliptin Ameliorates Glucose Fluctuations and Improves Glycemic Control Index in Japanese Patients with Type 2 Diabetes on Insulin Therapy 2014 ·Diabetes Technology & Therapeutics ·Seiichi Tanaka,Kunihiro Suzuki,Chie Aoki,(unknown),Kanako Kato,(unknown),Yoshimasa Aso	23
14	Alterations of plant sterols, lathosterol, oxidative stress and inflammatory markers after the combination therapy of ezetimibe and statin drugs in type 2 diabetic patients 2014 ·Obesity Research & Clinical Practice ·(unknown),(unknown),(unknown),Kenji Hara,Mariko Suetsugu,Kohzo Takebayashi,Kimio Morita,Yoshimasa Aso,Toshihiko Inukai	8
15	Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction 2009 ·Translational research ·Yoshimasa Aso,(unknown),Sadao Wakabayashi,Kenji Hara,(unknown),Mariko Suetsugu,Sachiko Matsumoto,(unknown),Kohzo Takebayashi,Kimio Morita,Toshihiko Inukai	26
16	Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus 2009 ·Experimental and Clinical Endocrinology & Diabetes ·Toshihiko Inukai,Rika Matsutomo,K. Tayama,Yoshimasa Aso,Y Takemura	19
17	Effects of losartan on serum total and high–molecular weight adiponectin concentrations in hypertensive patients with metabolic syndrome 2008 ·Metabolism ·Toshihiko Uchida,(unknown),Yoshihiko Sakai,(unknown),Kenji Hara,Kohzo Takebayashi,Teruo Inoue,Koichi Node,Toshihiko Inukai,Kan Takayanagi,Yoshimasa Aso	16
18	High Molecular Weight Adiponectin as a Predictor of Long-Term Clinical Outcome in Patients With Coronary Artery Disease 2007 ·The American Journal of Cardiology ·Teruo Inoue,Norihiko Kotooka,Toshifumi Morooka,Hiroshi Komoda,Toshihiko Uchida,Yoshimasa Aso,Toshihiko Inukai,Takehiko Okuno,Koichi Node	107
19	Comparison of the effects of pioglitazone and voglibose on circulating total and high‐molecular‐weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes 2007 ·Diabetic Medicine ·Yoshimasa Aso,Ruriko Yamamoto,Mariko Suetsugu,Sachiko Matsumoto,S. Wakabayashi,Rika Matsutomo,Kohzo Takebayashi,Toshihiko Inukai	22
20	High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes 2005 ·Metabolism ·Noboru Yoshida,Ki-ichi Okumura,Yoshimasa Aso	108

About Yoshimasa Aso

Yoshimasa Aso is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Internal Medicine, having authored 160 papers that have together received 4.3k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (30 papers), Adipokines, Inflammation, and Metabolic Diseases (22 papers) and Diabetes Management and Research (17 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.6k citations), Epidemiology (1.5k citations) and Clinical Biochemistry (287 citations). Yoshimasa Aso has collaborated with scholars based in Japan, United States and Austria. Frequent co-authors include Toshihiko Inukai, Kohzo Takebayashi, Sadao Wakabayashi, Teruo Jojima, Kunihiro Suzuki, Toshie Iijima, Mariko Suetsugu, K. Tayama, Ki-ichi Okumura and Sachiko Matsumoto. Their work appears in journals such as SHILAP Revista de lepidopterología, The Journal of Clinical Endocrinology & Metabolism and Diabetes Care.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact